---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-080026"
form_type: "8-K"
ticker: "HRTX"
cik: "0000818033"
company_name: "HERON THERAPEUTICS, INC. /DE/"
filed_at: "2024-07-02T23:59:59+00:00"
generated_at: "2026-05-31T23:52:02.367417+00:00"
event_type: "regulatory"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Heron Therapeutics announces FDA acceptance of ZYNRELEF VAN supplement; PDUFA goal date September 23, 2024

## Summary
- FDA acknowledged receipt of Prior Approval Supplement for ZYNRELEF Vial Access Needle (bupivacaine/meloxicam); PDUFA goal date September 23, 2024.
- If approved, VAN would replace vented vial spike, reducing withdrawal time from up to 3 minutes to 20-45 seconds.
- VAN expected to be available in Q4 2024 if approved; CrossLink partnership on track to add ~650 representatives by year-end.
- CEO Craig Collard expressed optimism that VAN and CrossLink partnership could increase adoption among orthopedic surgeons.

## SEC filing metadata
- accession: 0000950170-24-080026
- form_type: 8-K
- ticker: HRTX
- cik: 0000818033
- company_name: HERON THERAPEUTICS, INC. /DE/
- filed_at: 2024-07-02T23:59:59+00:00
- event_type: regulatory
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/818033/000095017024080026/0000950170-24-080026-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/818033/000095017024080026/hrtx-20240702.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-080026
- JSON: https://secwatch.observer/filing/0000950170-24-080026.json
- Plain text: https://secwatch.observer/filing/0000950170-24-080026.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.